**Federal marijuana rescheduling remains in a multi-step administrative process under the Controlled Substances Act.** In April 2026, the Department of Justice issued a final order immediately moving FDA-approved marijuana products and state-licensed medical cannabis to Schedule III, while recreational marijuana stayed in Schedule I. An expedited DEA hearing on broader rescheduling to Schedule III concluded in July 2026 after testimony from selected participants, followed by closing briefs in August. The administrative law judge is now reviewing the record to issue a recommendation to the DEA Administrator, with no statutory deadline for a final rule. Ongoing litigation challenges the process, though a September 2026 appeals court decision permitted it to continue. Trader sentiment reflects uncertainty over the remaining steps, potential court delays, and opposition from certain states and groups, despite the Trump administration’s December 2025 executive order directing expeditious completion.
Experimentelle KI-generierte Zusammenfassung mit Polymarket-Daten. Dies ist keine Handelsberatung und spielt keine Rolle bei der Auflösung dieses Marktes. · Aktualisiert$809,884 Vol.
31. Dez. 2026
30. September
2%
31. Dezember
16%
$809,884 Vol.
30. September
$660 Vol.
2%
31. Dezember
$199,654 Vol.
16%
This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), between market creation and September 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by July 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by March 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by June 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.**Federal marijuana rescheduling remains in a multi-step administrative process under the Controlled Substances Act.** In April 2026, the Department of Justice issued a final order immediately moving FDA-approved marijuana products and state-licensed medical cannabis to Schedule III, while recreational marijuana stayed in Schedule I. An expedited DEA hearing on broader rescheduling to Schedule III concluded in July 2026 after testimony from selected participants, followed by closing briefs in August. The administrative law judge is now reviewing the record to issue a recommendation to the DEA Administrator, with no statutory deadline for a final rule. Ongoing litigation challenges the process, though a September 2026 appeals court decision permitted it to continue. Trader sentiment reflects uncertainty over the remaining steps, potential court delays, and opposition from certain states and groups, despite the Trump administration’s December 2025 executive order directing expeditious completion.
This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
Markt eröffnet: Feb 7, 2026, 5:04 PM ET
Volumen
$809,884Enddatum
1. Jan. 2027Markt eröffnet
Feb 7, 2026, 5:04 PM ETAbwickler
0x65070BE91...This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), between market creation and September 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by July 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by March 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by June 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.**Federal marijuana rescheduling remains in a multi-step administrative process under the Controlled Substances Act.** In April 2026, the Department of Justice issued a final order immediately moving FDA-approved marijuana products and state-licensed medical cannabis to Schedule III, while recreational marijuana stayed in Schedule I. An expedited DEA hearing on broader rescheduling to Schedule III concluded in July 2026 after testimony from selected participants, followed by closing briefs in August. The administrative law judge is now reviewing the record to issue a recommendation to the DEA Administrator, with no statutory deadline for a final rule. Ongoing litigation challenges the process, though a September 2026 appeals court decision permitted it to continue. Trader sentiment reflects uncertainty over the remaining steps, potential court delays, and opposition from certain states and groups, despite the Trump administration’s December 2025 executive order directing expeditious completion.
This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
Volumen
$809,884Enddatum
1. Jan. 2027Markt eröffnet
Feb 7, 2026, 5:04 PM ETAbwickler
0x65070BE91...**Federal marijuana rescheduling remains in a multi-step administrative process under the Controlled Substances Act.** In April 2026, the Department of Justice issued a final order immediately moving FDA-approved marijuana products and state-licensed medical cannabis to Schedule III, while recreational marijuana stayed in Schedule I. An expedited DEA hearing on broader rescheduling to Schedule III concluded in July 2026 after testimony from selected participants, followed by closing briefs in August. The administrative law judge is now reviewing the record to issue a recommendation to the DEA Administrator, with no statutory deadline for a final rule. Ongoing litigation challenges the process, though a September 2026 appeals court decision permitted it to continue. Trader sentiment reflects uncertainty over the remaining steps, potential court delays, and opposition from certain states and groups, despite the Trump administration’s December 2025 executive order directing expeditious completion.
Experimentelle KI-generierte Zusammenfassung mit Polymarket-Daten. Dies ist keine Handelsberatung und spielt keine Rolle bei der Auflösung dieses Marktes. · Aktualisiert
Vorsicht bei externen Links.
Vorsicht bei externen Links.
Häufig gestellte Fragen